Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

Leukemia

Volumn 31, Issue 1, 2017, Pages 151-158

  Wang, K ^a,d   Sanchez Martin, M ^b   Wang, X ^c,e   Knapp, K M ^c   Koche, R ^c   Vu, L ^c   Nahas, M K ^a   He, J ^a   Hadler, M ^a   Stein, E M ^c   Tallman, M S ^c   Donahue, A L ^a   Frampton, G M ^a   Lipson, D ^a   Roels, S ^a   Stephens, P J ^a   Sanford, E M ^a   Brennan, T ^a   Otto, G A ^a   Yelensky, R ^a   Miller, V A ^a   Kharas, M G ^c   Levine, R L ^c   Ferrando, A ^b   Armstrong, S A ^c   Krivtsov, A V ^c   more..

^a FOUNDATION MEDICINE   (United States)

^b Institute for Cancer Genetics Columbia University ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ZHEJIANG CANCER HOSPITAL   (China)

^e Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; DNA METHYLTRANSFERASE 3A; FBXW7 PROTEIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLELE; ANIMAL EXPERIMENT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INDEL MUTATION; MAJOR CLINICAL STUDY; MIXED LINEAGE LEUKEMIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIMARY TUMOR; PRIORITY JOURNAL; SPLENIC TISSUE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ACUTE DISEASE; ADOLESCENT; ADULT; ANIMAL; BLOOD CELL; BONE MARROW TRANSPLANTATION; BOVINE; CHILD; GENE EXPRESSION PROFILING; GENETICS; LEUKEMIA; MIDDLE AGED; PATHOLOGY; TRANSPLANTATION; XENOGRAFT; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANIMALS; BLOOD CELLS; BONE MARROW TRANSPLANTATION; CATTLE; CHILD; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; MICE; MIDDLE AGED; YOUNG ADULT;

EID: 84976549470     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.166     Document Type: Article

References (35)

1. ADAM. Acute myeloid leukemia. ADAM Medical Encyclopedia 2014 May 29
2. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Adv Cancer Res 2010; 106: 113-164
3. Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 2013; 3: 295
4. Malaise M, Neumeier M, Botteron C, Dohner K, Reinhardt D, Schlegelberger B et al. Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice. Leukemia 2011; 25: 1635-1639
5. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23: 2109-2117
6. Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 2013; 121: e90-e97
7. Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 2015; 6: 6604
8. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-367
9. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163
10. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278
11. Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, O'Laughlin M et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014; 25: 379-392
12. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015; 15: 311-316
13. Vick B, Rothenberg M, Sandhofer N, Carlet M, Finkenzeller C, Krupka C et al. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PloS One 2015; 10: e0120925
14. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031
15. Cheng DT, Cheng J, Mitchell TN, Syed A, Zehir A, Mensah NY et al. Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data. J Mol Diagn 2014; 16: 504-518
16. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013; 4: 1116-1130
17. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 (Database issue): D805-D811
18. He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 2016 March 10
19. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074
20. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510
21. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005
22. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333
23. McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukaemia. Oncogene 2008; 27: 3765-3779
24. Xu D, Liu X, Yu WM, Meyerson HJ, Guo C, Gerson SL et al. Non-lineage/ stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. J Exp Med 2011; 208: 1977-1988
25. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93
26. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329-341
27. Distler E, Wolfel C, Kohler S, Nonn M, Kaus N, Schnurer E et al. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Exp Hematol 2008; 36: 451-463
28. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-299
29. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-575
30. Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005; 7: 179-191
31. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361
32. Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocytemacrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 2011; 117: 3076-3086
33. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014; 32: 364-372
34. Pandey KR, Maden N, Poudel B, Pradhananga S, Sharma AK. The curation of genetic variants: difficulties and possible solutions. Genomics Proteomics Bioinformatics 2012; 10: 317-325
35. Stein EM, Altman JK, Collins R, DeAngelo DJ, Fathi AT, Flinn I et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 2014; 2014, ASH abstract (115).